Incyte Licenses Two Treatments To Novartis
Incyte Corp. (Nasdaq: INCY) will license two blood disorder and cancer treatments to Novartis for $150 million upfront and an additional $60 million milestone payment. The stock price rose 76 cents to $8.48.